Project ProCorde
The members of the team look back on many years of common research experience on autoimmune and cardiovascular diseases. The foundation of Procorde initially created a common basis for pursuing research projects together and creating nature-derived antibodies, fusion proteins and peptides against acute or chronic cardiovascular and autoimmune diseases. Various therapeutic approaches have since been further developed in preclinical tests and clinical patient studies. In addition, novel RNA therapeutics and cellular immuntherapeutics are being developed.
The Team
- Prof. Dr. Martin Lohse, head (CEO) of ISAR Bioscience, Munich-Planegg, and former chairman of Max Delbrueck Centre for Molecular Medicine at Berlin Buch, vice president of the German Academy of Sciences Leopoldina, and former head of the Rudolf Virchow Center, University of Würzburg.
- Prof. Dr. Martin Ungerer, Cardiologist, Chief Scientific Officer (CSO) of ISAR Bioscience, Munich-Planegg
- Dr. Hans-Peter Holthoff, Chemist, Chief Technology Officer (CTO) of ISAR Bioscience, Munich-Planegg
- Prof. Dr. Götz Münch, Cardiologist, CEO of advancecor GmbH, Munich-Martinsried
- Prof. Dr. Meinrad Gawaz, Cardiologist, Director of Medical Clinic III, University of Tübingen, Germany
History
The team has initiated many projects in the first years after founding Procorde, which started in 2000. During this period, cooperations with large enterprises (e.g. Sanofi-Aventis) were carried out successfully. From 2007 on, relevant funding of the successor company Corimmun allowed further clinical development of the most promising drugs. In June 2012, Corimmun GmbH was sold to Janssen-CILAG GmbH, Neuss, a subsidiary of Johnson + Johnson, New Brunswick, NJ, USA. A price of 100 million USD was paid subsequently, and further milestone-dependent payments and royalties were agreed. Since 2020, many members of the team have been working at ISAR Bioscience. Planegg. ISAR Bioscience has embarked on many novel avenues, including lipid nanoparticles (LNP) and other RNA therapeutics, monoclonal antibodies and stem cell-derived immune cells for immunotherapies.
